Drugs / RO5428029
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01371162 | Jun → Dec 2011 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01345942 | May → Jun 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5428029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345942 ↗ |
| Action | Inhibit | “HCV Nucleoside Inhibitor RO5428029” NCT01371162 ↗ |
| Modality | Small molecule | “HCV Nucleoside Inhibitor RO5428029” NCT01371162 ↗ |
| Route | Oral | “single oral dose of RO5428029” NCT01345942 ↗ |